Craig-Hallum Maintains Simulations Plus(SLP.US) With Buy Rating
Craig-Hallum Maintains Simulations Plus(SLP.US) With Buy Rating
Craig-Hallum Maintains Simulations Plus(SLP.US) With Buy Rating
Craig-Hallum Maintains Simulations Plus(SLP.US) With Buy Rating
Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Diamedica Therapeutics (DMAC)
Simulations Plus Analyst Ratings
Oppenheimer Maintains Simulations Plus(SLP.US) With Buy Rating, Maintains Target Price $65
Simulations Plus (SLP) Receives a Buy From Oppenheimer
Simulations Plus Analyst Ratings
KeyBanc Initiates Simulations Plus(SLP.US) With Buy Rating, Announces Target Price $47
KeyBanc Maintains Simulations Plus(SLP.US) With Buy Rating, Maintains Target Price $47
Simulations Plus (SLP) Gets a Buy From KeyBanc
Simulations Plus Analyst Ratings
Buy Rating Affirmed for Simulations Plus Amidst Strong Growth and Strategic Acquisitions
Craig-Hallum Reiterates Buy on Simulations Plus, Maintains $56 Price Target
Simulations Plus Analyst Ratings
Simulations Plus Analyst Ratings
Strong Buy Rating for Simulations Plus: A Resilient Market Leader Poised for Sustainable Growth
Craig-Hallum Remains a Buy on Simulations Plus (SLP)
Analysts Offer Insights on Healthcare Companies: PAVmed (PAVM) and Simulations Plus (SLP)